No Data
Fengyuan Pharmaceutical: Report for the third quarter of 2024
Anhui Fengyuan Pharmaceutical (000153.SZ) released its performance for the first three quarters, with a net income of 0.147 billion yuan, a year-on-year increase of 3.40%.
Anhui Fengyuan Pharmaceutical (000153.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Anhui Fengyuan Pharmaceutical (000153.SZ): The net income in the first three quarters was 0.147 billion yuan, a year-on-year increase of 3.40%.
Gelonghui October 30th | Anhui Fengyuan Pharmaceutical (000153.SZ) released the third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 3.261 billion yuan, a year-on-year increase of 1.16%; net income attributable to shareholders of the listed company was 0.147 billion yuan, a year-on-year increase of 3.40%; net income after deducting non-recurring gains and losses was 0.118 billion yuan, a year-on-year decrease of 9.64%; basic earnings per share 0.3169 yuan/share.
Anhui Fengyuan Pharmaceutical (000153.SZ): The company's product physiological saline is currently not exported to the usa.
Georg-Lonhui October 25th | Anhui Fengyuan Pharmaceutical (000153.SZ) stated on the investor interaction platform that the company's product physiological saline is currently not exported to the usa.
Do Its Financials Have Any Role To Play In Driving Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) Stock Up Recently?
Fengyuan Pharmaceutical: 2024 Semi-Annual Report
Little Excitement Around Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) Earnings As Shares Take 26% Pounding
